Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: A randomized controlled trial

JAMA

Volumn 282, Issue 2, 1999, Pages 137-144

  Nichol, Kristin L ^a   Mendelman, Paul M ^b   Mallon, Kenneth P ^b   Jackson, Lisa A ^b   Gorse, Geoffrey J ^b   Belshe, Robert B ^b   Glezen, W Paul ^b   Wittes, Janet ^b  

^a VA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ABSENTEEISM; ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INTRANASAL DRUG ADMINISTRATION; NORMAL HUMAN; PRIORITY JOURNAL; WORK DISABILITY;

EID: 0033554086     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.2.137     Document Type: Article

References (34)

1. Couch RB. Advances in influenza virus vaccine research. Ann N Y Acad Sci. 1993;685:803-812.
2. Riddiough MA, Sisk JE, Bell JC. Influenza vaccination: cost-effectiveness and public policy. JAMA. 1983; 249:3189-3195.
3. Sullivan KM, Monto AS, Longini IM Jr. Estimates of the US health impact of influenza. Am J Public Health. 1993;83:1712-1716.
4. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 1999;48(RR-4):1-29.
5. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med. 1995;333:889-893.
6. Clements ML, Betts RF, Murphy BR. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wildtype virus infection. Lancet. 1984;1:705-708.
7. Gorse GJ, Belshe RB, Munn NJ. Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults. Chest. 1991; 100:977-984.
8. Gorse GJ, Campbell MJ, Otto EE, et al. Increased anti-influenza A virus cytotoxic T-cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine. J Infect Dis. 1995;172:1-10.
9. Gorse GJ, Otto EE, Powers DC, et al. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly. J Infect Dis. 1996;173:285-290.
10. Clover RB, Crawford S, Glezen WP, et al. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. J Infect Dis. 1991; 163:300-304.
11. Piedra PA, Glezen WP, Influenza in children: epidemiology, immunity, and vaccines. Semin Pediatr Infect Dis. 1991;2:140-146.
12. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998;338:1405-1412.
13. Clements ML, O'Donnell S, Levine MM, et al. Dose response of A/Alaska/6/77 cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine. Infect Immun. 1983;40:1044-1051.
14. Murphy BR, Clements ML, Madore HP, et al. Dose response of cold-adapted, reassortant influenza A/California/10/78 virus (H1N1) in adult volunteers. J Infect Dis. 1984;149:814-816.
15. Clements ML, Snyder MH, Sears SD, et al. Evaluation of the infectivity, immunogenicity, and efficacy of cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers. J Infect Dis. 1990;161:869-877.
16. Treanor JJ, Betts RF. Evaluation of live attenuated cold-adapted influenza B/Yamagata/16/88 reassortant virus vaccine in healthy adults. J Infect Dis. 1993;168:455-459.
17. Treanor JJ, Betts RF, Kotloff K, et al. Efficacy of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A(H1N1) A(H3N2), and B viruses. Vaccine. In press.
18. Edwards KM, Dupont WD, Westlich MK, et al. A randomized controlled trial of cold-adapted and inactivated vaccine for the prevention of influenza A disease. J Infect Dis. 1994;169:68-79.
19. Centers for Disease Control and Prevention. Update: influenza activity - United States and worldwide, 1996-97 season, and composition of the 1997-98 influenza vaccine, MMWR Morb Mortal Wkly Rep. 1997;46:325-330.
20. Zeigler BL, Bulley N. A voice information system supporting compliance in the Aviron FluMist vaccine trial. In: Proceedings of the 4th Workshop on Interactive Voice Technology for Telecommunications Applications (IVTTA); September 29-30,1998; Torino, Italy.
21. Centers for Disease Control and Prevention. Update: influenza activity - United States, 1997-98 season. MMWR Morb Mortal Wkly Rep. 1998;47: 196-200.
22. Centers for Disease Control and Prevention. Update: influenza activity - United States and worldwide, 1997-98 season, and composition of the 1998-99 influenza vaccine. MMWR Morb Mortal Wkly Rep. 1998;47:280-284.
23. Gruber W, Belshe R, Mendelman P, et al. Immunologic response to heterotypic H3N2 strains after live intranasal or inactivated intramuscular influenza vaccine in children: abstracts of the IDSA 36th Annual Meeting. Clin Infect Dis. 1998;27:933.
24. Belshe R, Iacuzio D, Mendelman P, Wolff M. Efficacy of a trivalent live attenuated intranasal influenza vaccine in children. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 24-27,1998; San Diego, Calif.
25. Bridges CB, Fukuda K, Thompson W, et al. Cost effectiveness of influenza vaccine against a drifted influenza A(H3N2) strain among healthy adults, 1997-98. In: Program and abstracts of the Infectious Diseases Society of America 36th Annual Meeting; November 12-15, 1998; Denver, Colo.
26. Edmondson WP Jr, Rothenberg R, White PW, Gwaltney JM Jr. A comparison of subcutaneous, nasal, and combined influenza vaccination, II: protection against natural challenge. Am J Epidemiol. 1971; 93:480-486.
27. Edmondson KW, Graham DSM, Warburton MF. A clinical trial of influenza vaccine in Canberra. Med J Aust. 1970;2:6-13.
28. Batey D. A case study of influenza vaccine and its impact on absenteeism in the work place: a randomized clinical trial at Exxon Company, USA. Presented at: Work Group Meeting on Improving the Performance of Influenza and Pneumococcal Vaccines in Older Adults; November 14-15, 1995; Washington, DC.
29. Smith JWG, Pollard R. Vaccination against influenza: five-year study in the Post Office. J Hyg. 1979; 83:157-170.
30. Leighton L, Williams M, Aubery D, Parker SH. Sickness absence following a campaign of vaccination against influenza in the workplace. Occup Med. 1996; 46:146-150.
31. Wilde MA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA. 1999;281:908-913.
32. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA. 1997;278:901-904.
33. Schwartz B, Bell DM, Hughes JM. Preventing the emergence of antimicrobial resistance: a call for action by clinicians, public health officials, and patients. JAMA. 1997;278:944-945.
34. Orts K, Sheridan JF, Robinson-Whelen S, et al. The reliability and validity of a structured interview for the assessment of infectious illness symptoms. J Behav Med. 1995;18:517-529.